ArticleJournal of burn care & research : official publication of the American Burn Association2025
Ibuprofen is Not Associated With an Elevated Bleeding Risk or Transfusion Requirement in Skin Grafting for Patients With Burn Injuries.
Article in Journal of burn care & research : official publication of the American Burn Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Postoperative Analgesic Outcomes Following Pre-Induction Intravenous Ibuprofen in Children Undergoing Hypospadias Repair: A Randomized Controlled Study.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibuprofen, a non-steroidal anti-inflammatory drug, can increase the risk of bleeding, a significant concern in burn surgery, which often involves substantial blood loss. This study aims to evaluate the safety of ibuprofen use in burn patients undergoing skin grafting. A retrospective case-control chart review was conducted for patients admitted with acute burn injury from January 1, 2024 to July 31, 2024 who underwent skin grafting. The primary outcome variables included perioperative transfusion requirement, bleeding, skin graft failure, and other complications. A total of 53 patients met the inclusion criteria, 24 (45.2%) of whom received scheduled ibuprofen therapy during their hospitalization. The total body surface area affected was 12.3 ± 9.3% for the non-ibuprofen group and 14.3 ± 12.1% for the ibuprofen group (P = .62). A total of 79.3% of patients in the non-ibuprofen group received meshed grafts compared to 79.2% in the ibuprofen group (P = .734). Perioperative transfusion requirements were similar between the 2 cohorts, averaging 4.6 ± 3.1 for the non-ibuprofen group and 3.2 ± 2.8 units of packed red blood cells for the ibuprofen group (P = .207). Skin graft failure (defined as the need for re-grafting) occurred in 6.9% (n = 2) of the non-ibuprofen cohort vs none (n = 0) in the ibuprofen group (P = .112). Postoperative complications did not vary significantly between the 2 groups for seroma (P = .259), hematoma (P = .498), and infection (P = .568). There were no cases of hypersensitivity or gastrointestinal bleeding. There is likely no increased risk of bleeding or skin graft failure in burn injury patients taking ibuprofen, suggesting that these medications may be safe in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.